Commodity Channel Index
|Bid||155.51 x 1000|
|Ask||155.99 x 1000|
|Day's Range||155.28 - 159.72|
|52 Week Range||88.69 - 178.50|
|Beta (5Y Monthly)||1.32|
|PE Ratio (TTM)||31.73|
|Earnings Date||Sep 15, 2020|
|Forward Dividend & Yield||2.60 (1.67%)|
|Ex-Dividend Date||Jun 26, 2020|
|1y Target Est||168.64|
What happened Shares in United Parcel Service (NYSE: UPS) rose 11.5% in June, according to data provided by S&P Global Market Intelligence. In common with its direct peer FedEx (NYSE: FDX), which rose 7.
The review follows a fresh wave of calls to scrap a team name long-criticised as racist.
Investors might take some big earnings beats as a sign that business is improving faster than it really is. That could set up stocks for a big rally that could end in tears.
FedEx Corp. , which pays for naming rights to the Washington Redskins' stadium in Maryland, has asked the team to change its controversial name. "We have communicated to the team in Washington our request that they change the team name," FedEx said in a statement to the media Thursday. FedEx Chief Executive Fred Smith is also a minority owner of the team. The team name has been criticized as racist for years, but team owner Daniel Snyder has been under increasing pressure recently amid the national reckoning on race relations. Earlier this week, AdWeek reported that nearly 90 investment firms and shareholders have asked FedEx, Nike Inc. and PepsiCo Inc. to cancel their business relationships with the team until it agrees to change its name, and the Washington Post reported Wednesday that Snyder will not be permitted to build a new stadium in Washington unless the team name is changed.
Zacks Market Edge Highlights: Nike, FedEx, Microsoft, JPMorgan Chase and Bank of America
Jim Cramer shares stock market news including FedEx price target moving higher, Apple's new 5G iPhone, and trading Pfizer shares after positive vaccine news.
Companies in the news are: M, FDX, BYND, TTOO
FedEx (FDX) saw a big move last session, as its shares jumped nearly 12% on the day, amid huge volumes.
The number of confirmed cases of the coronavirus illness COVID-19 in the U.S. climbed above 2.6 million on Wednesday, a day after Dr. Anthony Fauci said it could spike to more than 100,000 a day if the fresh clusters emerging in the South and West are not brought under control.
The Dow finished lower Wednesday, but the tech-heavy Nasdaq was vaulted to a fresh record close, giving the year’s second half a mixed start as investors focused on signs of economic recovery from the coronavirus crisis and a new Fed promise for clarity on the path of rates.
The S&P 500 and Nasdaq indexes closed higher on Wednesday to kick off the third quarter as increasing optimism for a safe and effective COVID-19 vaccine eased concerns that another round of business lockdowns was likely. Pfizer Inc's shares rose more than 3% after the drugmaker said a COVID-19 vaccine being developed with German biotech firm BioNTech showed promise and was found to be well-tolerated in early-stage human trials.
J.P. Morgan analyst Brian Ossenbeck was impressed with the earnings “print,” saying the company delivered during tough times. “FedEx set a more constructive tone on raising the price of capacity,” wrote the analyst in a Wednesday research report. FedEx is beginning to apply residential peak surcharges after years of not doing so.
On Wednesday, JPMorgan analyst Brian Ossenbeck upgraded shares of FedEx to overweight with a $188 price target after the courier reported “a solid EPS beat in tough conditions.” Looking ahead, the firm thinks FedEx’s quarterly results could be good news for when UPS reports. The Final Round panel discusses.
United Parcel Service shares on Wednesday were climbing, buoyed by rival delivery service FedEx , which beat Wall Street's quarterly expectations. Shares of UPS, Atlanta, at last check were up 3.5% to $115.02, while FedEx, Memphis, jumped 12% to $157.11. XPO Logistics did not benefit from FedEx's good fortune.
U.S. stocks moved higher on Wednesday as rising hopes of a safe and effective COVID-19 vaccine eased concerns another round of lockdowns was likely following a record surge in coronavirus cases in the United States. Pfizer Inc's shares rose nearly 5% after the drugmaker said a COVID-19 vaccine being developed with German biotech firm BioNTech showed promise and was found to be well-tolerated in early-stage human trials.
The Dow Jones wasn't moving much in afternoon trading Wednesday, but Pfizer stock rose sharply on positive coronavirus vaccine data.
FedEx gapped sharply today in reaction to FQ4 results that topped expectations. The company said that while commercial volumes were down significantly due to business closures, surges in residential deliveries at FedEx Ground, and in transpacific and charter flights at FedEx Express, provided an offset.
Wall Street's main indexes gained on Wednesday as rising hopes of a safe and effective COVID-19 vaccine allayed some fears of another round of lockdowns following a record surge in coronavirus cases in the United States. A COVID-19 vaccine developed by Pfizer Inc and German biotech firm BioNTech showed promise and was found to be well tolerated in early-stage human trials, the companies said. Pfizer's shares rose about 5% on the news, one of the biggest boost to the S&P 500 index, while BioNTech gained 7%, helping improve the mood on Wall Street after the United States registered 47,000 new coronavirus cases on Tuesday, the biggest one-day spike since the start of the pandemic.
Stocks kicked off Q2 with early gains on coronavirus drug news, though the Dow Jones Industrial Average was nearly flat after a 207-point jump.
S&P 500 earnings are expected to fall 44.1% in Q2 but there will likely be surprises as many companies withdrew guidance.
The S&P 500 and Nasdaq rose on Wednesday as rising hopes of a COVID-19 vaccine offset fears of another round of lockdowns following a record surge in coronavirus cases in the United States. A COVID-19 vaccine developed by Pfizer Inc and German biotech firm BioNTech showed promise and was found to be well tolerated in early-stage human trial, the companies said.